Press Releases

01 Feb, 2024, 16:00 ET CRANBURY, N.J., Feb. 1, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 1,831,503 shares of

30 Jan, 2024, 08:00 ET CRANBURY, N.J., Jan. 30, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for

08 Jan, 2024, 10:33 ET Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients Interim Analysis Data Readout on Track for 1Q Calendar Year 2024 Topline Results

20 Dec, 2023, 07:30 ET Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin’s focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, N.J., Dec. 20, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based

18 Dec, 2023, 16:15 ET CRANBURY, N.J., Dec. 18, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the “Exchange”) approving Palatin’s plan (the

14 Nov, 2023, 07:30 ET Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for 1Q Calendar Year 2024 Topline Results Currently Expected in

09 Nov, 2023, 07:30 ET CRANBURY, N.J., Nov. 9, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

24 Oct, 2023, 16:50 ET CRANBURY, N.J., Oct. 24, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 2,358,491 shares of

23 Oct, 2023, 07:30 ET CRANBURY, N.J., Oct. 23, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with an institutional investor for